Alector_logo (1).png
Alector Announces First Alzheimer’s Disease Patient Dosed in Phase 1b Study of AL002
May 06, 2019 06:30 ET | Alector, Inc.
- Phase 1b study of AL002 enrolling Alzheimer’s disease patients will assess safety and pharmacodynamics, and will monitor target specific biomarkers SOUTH SAN FRANCISCO, Calif., May 06, 2019 ...
Alector_logo (1).png
Alector Announces First Frontotemporal Dementia Patient Dosed in Phase 1b Study of AL001
April 17, 2019 16:05 ET | Alector, Inc.
Phase 1 healthy volunteer portion of the AL001 study successfully met its primary objective of safety and demonstrated proof-of-mechanism in the central nervous system (CNS)Phase 1b study of AL001...
Alector_logo (1).png
Alector Initiates Phase 1 Trial of AL003 for the Treatment of Patients with Alzheimer’s Disease
April 01, 2019 16:30 ET | Alector, Inc.
- AL003 is Alector’s second program targeting Alzheimer’s disease and its third program in the clinic SOUTH SAN FRANCISCO, Calif., April 01, 2019 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a...
Alector_logo (1).png
Alector Reports Recent Business Highlights and Fourth Quarter and Full Year 2018 Financial Results
March 26, 2019 16:15 ET | Alector, LLC
- Strong 2018 marked by the company’s first and second programs entering the clinic, targeting frontotemporal dementia and Alzheimer’s disease. Ten programs in Research and Development and two in...
Alector_logo (1).png
Alector to Present at Investor Conferences in March
March 06, 2019 17:15 ET | Alector, LLC
SOUTH SAN FRANCISCO, Calif., March 06, 2019 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the...